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subjects (responders 7,736) from the population-based Malmö Diet and
Cancer cohort. A random sample of 1,300 subjects with chronic knee pain
(duration of at least one month in the last year), and a control group of
650 subjects, were invited to a clinical examination including x-ray of both
knees (998 + 487 subjects underwent examination and x-ray). Subjects
who fulﬁlled ACR criteria and/or had radiographic knee OA (ROA) were
considered to have knee OA. The EQ-5D index states were converted into a
single index value according to the UK TTO value set. A normalized score
was calculated for each KOOS and WOMAC subscale, and for the WOMAC
total score. Data were analysed using analysis of variance with age, sex,
and BMI as covariates.
Results: Approximately 20% (1,605/7,736) of the subjects had chronic knee
pain. Of those that participated in the examination and x-ray, 50% (502/998)
had knee OA. Subjects with knee OA were to a larger extent women (63%
vs. 57%, p=0.05), had higher mean age, and BMI than controls (mean age:
70.2 vs. 69.2 years, p<0.05; BMI: 29.0 vs. 26.3 kg/m2, p<0.01). Subjects with
knee OA reported signiﬁcantly worse scores compared to those without
knee OA in all HRQL instruments. Subjects fulﬁlling ACR criteria reported
signiﬁcantly worse scores than those with ROA only, according to all HRQL
instruments. Subjects of age 75≥ reported signiﬁcantly worse scores than
subjects of age <65 in all KOOS subscales but Symptoms, in EQ-5D index, in
all WOMAC subscales but Stiffness, and in the WOMAC total score. Subjects
with BMI >30 kg/m2 reported signiﬁcantly worse scores than subjects with
BMI <25 in all HRQL instruments. Females reported signiﬁcantly worse
scores than males in all HRQL instruments and subscales, except KOOS QoL
and EQ-5D index.
Conclusions: In this population-based study, those fulﬁlling ACR criteria
were associated with signiﬁcantly worse generic and disease-speciﬁc qual-
ity of life compared to those having ROA only. In general, being a woman,
being old, or having high BMI was associated with worse outcome.
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Purpose: Knee osteoarthritis is a real public health problem. According to
data from the Framingham study, its prevalence is estimated to be 6.1% of
adults over the age of 30. This prevalence increases with age, to more than
40% after the age of 75. Knee osteoarthritis is generally not life-threatening,
but it does signiﬁcantly affect the daily lives of patients who have it and
incurs very high costs for the community
Methods: Pragmatic, longitudinal and prospective follow-up carried out
by rheumatologists in the context of their daily professional activities;
the investigator does not change the prescription or management habits.
The objective is to observe, under actual conditions of use, the effect
obtained, in the context of management of knee osteoarthritis, combining
a prescription of Avian ACS (Structum® - 1 g/day) between 2 courses of
treatment of 3 injections of hyaluronic acid (Structovial®) spaced out by a
maximum of 12 months.
Results: 200 patients are treated with Structovial® and Structum® , and
the gender ratio favours women (64% versus 36%).The average age is
65.30 years (±7.10); men are not statistically younger than women. While
height and weight are different for men and women, the Body Mass Index
calculated does not differ by gender: 28.80±5.95 for the women versus
60.15±14.13 for the men (p=0.35). 50% percent of the patients are treated
for their left knee and 50% are treated for their right knee.
Average pain during activities of daily living was measured by means of a
visual analogue scale. It is 52.02±20.53 at inclusion.
At 6 months, this same average pain measured under the same conditions is
33.58±25.21. A third measurement at 12 months situates it at 30.44±22.86.
Pain during activities of daily living is signiﬁcantly reduced between in-
clusion and month 6 (p<0.0001) and between inclusion and month 12
(p<0.0001). The average reduction in pain during activities of daily living
measured between inclusion and 12 months is also signiﬁcant (p<0.0001).
Accordingly, the reduction obtained in 12 months is 41%. With regard to
pain measured at rest, it was also measured at inclusion, at 6 months and
at 12 months, by means of a visual analogue scale. There is a signiﬁcant
reduction in pain at rest between inclusion and 6 months (p=0.0052)
and the reduction between inclusion and month 12 is also signiﬁcant
(p=0.0005). At inclusion, at 6 months and at 12 months, the average pain
observed is 29.86±21.16, 20.95±23.13 and 17.33±6.97, respectively.
Conclusions: During a previous non-inferiority, randomised, controlled
trial, Structovial® showed proof of its non-inferiority compared with a base-
line high molecular weight hyaluronic acid (Synvisc®). With Structovial®,
improvement is observed early (week 6); this improvement is maintained
at 6 months. Moreover, overall clinical improvement is manifested in an
improvement in quality of life [5].
In addition, in another study, 256 subjects with knee osteoarthritis were
randomised into 2 groups: 127 randomised subjects were placed in the
group treated with Avian ACS (Structum®) and 129 randomised subjects
were placed in the group receiving the placebo. At inclusion, the PCS-12 in-
dex (Physical Component) was 36.43 and 36.64, respectively, for the group
treated with Avian ACS (Structum®) and the group receiving the placebo.
The 2 groups were similar at inclusion. After 6 months of treatment, the
PCS-12 index was 42.25 and 39.47, respectively, for the group treated
with Avian ACS (Structum®) and the group receiving the placebo. There
was a statistically signiﬁcant improvement in the score of the physical
component for the group of patients to treat with Avian ACS (Structum®)
compared with that of the placebo group (p<0.05).
Our study, which assesses the effect on pain obtained in the context of
management of subjects with knee osteoarthritis, combining a prescription
of Structum® (1 g/day) between 2 courses of treatment of 3 injections of
Structovial®, showed a reduction in pain during activities of daily living.
This reduction in pain, which is signiﬁcant at 6 months, then perpetuated
at 12 months, shows the relevance of the treatment protocol used by the
doctors.
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Purpose: The objective of the study was to assess the burden of os-
teoarthritis (OA) across different countries.
Methods: A structured literature review was conducted to assess the
burden of osteoarthritis worldwide using Medline (year 1995 to 2009).
Keywords included (but not limited to): osteoarthritis, prevalence, burden
of illness, treatment, quality of life, and cost. Search was limited to articles
written in English.
Results: Published studies on burden of OA were found in 20 countries.
Overall prevalence rates have been reported between 4 to 57% across
different countries. Japan had the most published prevalence studies with
rates reported as low as 4% to as high as 56%. Despite differences in
prevalence, all studies consistently reported OA to be more prevalent in
women than men.
Although all joints in the body may be affected by OA, the knee, fol-
lowed by the hip and hand, were found most common. The literature
review found a lack of any true disease-modifying OA drug; consequently,
treatments were targeted at the reduction of pain and inﬂammation and
maintenance of function. The literature ﬁndings also found no major
changes in recent years to the treatment and management of OA, which
primarily involves pain palliation and maintenance of function. Among
guidelines, there was general consensus that a combination of pharmaco-
logical and non-pharmacological modalities should be used in management
of OA. Most common non-pharmacological interventions reported include
exercise, weight reduction, and patient education. Across all countries,
pharmacological interventions are aimed to reduce pain and mainly consist
of acetaminophen (paracetamol) and NSAIDs with opioid use varying by
geographical location. While NSAIDs are the most frequently used therapy
worldwide, it is associated with well-documented adverse events such as
GI discomfort, bleeding, ulceration, and perforation.
Patients’ functioning and quality of life were also reported in many studies
to be negatively affected by the burden of OA pain. Other symptoms (e.g.
sleep disturbance, depression, fatigue, and anxiety) were also found to
be associated with OA. Furthermore, OA patients were reported to have
reduced activities of daily living, social isolation, and limitations in regards
to career advancement.
The economic burden of OA have been highlighted in a number of reviewed
studies and have been estimated to cost the US economy nearly $128
billion per year in medical care and indirect expenses (including lost
wages and productivity) with individual studies reporting an average of
$18,000 per OA patient per year. Globally, OA represents a huge economic
challenge. The average annual total cost that have been reported across all
